ArticleJournal of clinical hypertension (Greenwich, Conn.)2021
Hypertension-mediated organ damage regression associates with blood pressure variability improvement three years after successful treatment initiation in essential hypertension.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- An epidemiological assessment of the distribution and sociodemographic burden of chronic diseases: a focus on hypertension, diabetes, and cardiovascular conditions.Frontiers in epidemiology · 2026Article
- Short-term blood pressure variability assessed by ambulatory blood pressure monitoring as a predictor of subclinical target organ damage.Frontiers in cardiovascular medicine · 2026Article
- Brazilian Guidelines of Hypertension - 2025.Arquivos brasileiros de cardiologia · 2025Article
- A Pilot Human Study on Dual Photoplethysmography for Continuously Monitoring Pulse Wave Velocity and Blood Pressure.IEEE journal on flexible electronics · 2025Article
- Blood pressure variability: a review.Journal of hypertension · 2025Review
- Evaluating SCUBE-1 as Predictive Biomarker for Hypertension-Mediated Organ Damage: A Comparative Study.Reviews in cardiovascular medicine · 2025Article
- Association between short-term blood pressure variability and target organ damage in non-dialysis patients with chronic kidney disease.BMC nephrology · 2024Article
- Association of blood pressure variability with target organ damage in older patients with essential hypertension.Chronic diseases and translational medicine · 2023Article
- Ambulatory blood pressure monitoring in children: A retrospective single-center study.Frontiers in pediatrics · 2023Article
- High incidence of hypertension-mediated organ damage in a series of Chinese patients with 17α-hydroxylase deficiency.Endocrine · 2022Article
- Is Thoracic Aortic Diameter an Independent Predictor of Cardiovascular Disease and Mortality? A Narrative Review.Frontiers in cardiovascular medicine · 2022Review
- Should reduction of increased short-term blood pressure variability be a target of antihypertensive therapy?Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Hypertension-mediated organ damage regression associates with blood pressure variability improvement three years after successful treatment initiation in essential hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Blood pressure variability and target organ damage regression in hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood pressure variability (BPV) has been associated with the development, progression, and severity of cardiovascular (CV) organ damage and an increased risk of CV morbidity and mortality. We aimed to explore any association between short-term BPV reduction and hypertension-mediated organ damage (HMOD) regression in hypertensive patients 3-year post-treatment initiation regarding BP control. 24-h ambulatory blood pressure monitoring (24 h ABPM) was performed at baseline in 180 newly diagnosed and never-treated hypertensive patients. We measured 24 h average systolic (24 h SBP) and diastolic BP (24 h DBP) as well as 24 h systolic (sBPV) and diastolic BPV (dBPV). Patients were initially evaluated and 3 years later regarding arterial stiffness (PWV), left ventricular hypertrophy (LVMI), carotid intima-media thickness (cIMT), 24 h microalbumin levels (MAU), and coronary flow reserve (CFR). Successful BP treatment was defined as 24 h SBP/DBP < 130/80 mm Hg based on 2nd ABPM and subsequently, patients were characterized as controlled (n = 119, age = 53 ± 11 years) or non-controlled (n = 61, age = 47 ± 11 years) regarding their BP levels. In the whole population and the controlled group, 24 h SBP/DBP, sBPV/dBPV, LVMI, and IMT were decreased. Additionally, LVMI improvement was related with both sBPV (p < .001) and dBPV reduction (r = .18, p = .02 and r = .20, p = .03, respectively). In non-controlled hypertensives, PWV was increased. In multiple linear regression analysis, sBPV and dBPV reduction predicted LVMI improvement in total population and controlled group independently of initial office SBP, mean BP, and 24 h-SBP levels. In middle-aged hypertensive patients, a 3-year antihypertensive treatment within normal BP limits, confirmed by 24-h ABPM, leads to CV risk reduction associated with sBPV and dBPV improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.